OMass Therapeutics, a University of Oxford spin-out developing small-molecule drugs.
Why it matters: The round shows how European biotech investors are concentrating capital on platform-based drug discovery, with OMass's native mass spectrometry approach now funded through Phase 2.
British clinical-stage biopharma company Microbiotica announced the first close of a €42 million Series C round led by British Business Bank.
Why it matters: Microbiotica's Series C first close shows how genomics and machine learning are moving microbiome drug candidates into Phase 2 trials.
Abby Care, an AI-native home care startup that trains family members to become certified.
Why it matters: Abby Care's $82M Series C shows investors backing an AI-native Medicaid provider that trains and pays family caregivers, a model aimed at the home care labor gap.
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing
